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Abstract
Libman-Sacks endocarditis of the mitral valve was first described by Libman and Sacks in 1924. Currently, the sterile
verrucous vegetative lesions seen in Libman-Sacks endocarditis are regarded as a cardiac manifestation of both sys-
temic lupus erythematosus (SLE) and the antiphospholipid syndrome (APS). Although typically mild and asympto-
matic, complications of Libman-Sacks endocarditis may include superimposed bacterial endocarditis,
thromboembolic events, and severe valvular regurgitation and/or stenosis requiring surgery. In this study we report
two cases of mitral valve repair and two cases of mitral valve replacement for mitral regurgitation (MR) caused by
Libman-Sacks endocarditis. In addition, we provide a systematic review of the English literature on mitral valve sur-
gery for MR caused by Libman-Sacks endocarditis. This report shows that mitral valve repair is feasible and effective
in young patients with relatively stable SLE and/or APS and only localized mitral valve abnormalities caused by
Libman-Sacks endocarditis. Both clinical and echocardiographic follow-up after repair show excellent mid- and
long-term results.
Introduction
In 1924 Libman and Sacks first described four cases of
non-bacterial verrucous vegetative endocarditis [1]. The
sterile verrucous lesions of Libman-Sacks (LS) endocar-
ditis (Fig 1) show a clear predisposition for the mitral
and aortic valves and are nowadays seen as both a car-
diac manifestation of systemic lupus erythematosus
(SLE) and, more recently, of the antiphospholipid syn-
drome (APS) [2-5].
SLE is an autoimmune disorder resulting in multi-
organ inflammatory damage. Over the last decades with
prolonged survival and improvement in diagnostic tech-
niques, particularly in echocardiography, cardiac disease
associated with SLE has become more apparent [6,7]. A
recent echocardiographic study in patients with SLE
revealed that LS vegetations can be found in approxi-
mately 11% of patients with SLE [8]. In 63% of these
patients with vegetations the mitral valve was involved
[8]. Earlier echocardiographic studies reported a higher
prevalence of LS vegetationsi np a t i e n t sw i t hS L E ,r a n -
ging from 53% to 74% [9,10].
Antiphospholipid syndrome (APS) has been defined as
venous or arterial thrombosis, recurrent fetal loss, or
thrombocytopenia accompanied by increased levels of
antiphospholipid antibodies (aPLs) (i.e anticardiolipin
antibodies and the lupus anticoagulant) [11-14]. This
syndrome can be either primary or secondary to an
underlying condition (most commonly SLE) [11-14]. An
echocardiographic study in patients with primary APS
showed that approximately one third of these patients
have LS valvular lesions [4]. SLE is frequently accompa-
nied by the presence of aPLs, which is associated with a
higher prevalence of valvular abnormalities in SLE
patients [5,15].
Although typically mild and asymptomatic, LS endocar-
ditis can lead to serious complications, including superim-
posed bacterial endocarditis, thromboembolic events,
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valvular regurgitation and/or stenosis requiring surgery.
The literature on mitral valve surgery for mitral regur-
gitation (MR) caused by LS endocarditis is compara-
tively sparse. In this study we report two cases of mitral
valve repair and two cases of mitral valve replacement
for MR caused by LS endocarditis. In addition, we pro-
vide a systematic review of the English literature on
mitral valve surgery for MR caused by LS endocarditis.
Case Reports
We analyzed our institution’s mitral valve surgery data-
base and found four patients who underwent mitral
valve surgery for MR caused by LS endocarditis in the
period 1995-2008.
Patient 1
A 49-year-old Caucasian man presented at our institu-
tion with SLE that had been diagnosed originally in
August 1996. Manifestations of his disease included
arthritis, a rash on sun-exposed skin, and skin lesions
resembling urticaria. Laboratory findings are shown in
Table 1. A skin biopsy revealed urticarial vasculitis.
There was no evidence of cerebral or renal involeve-
ment. His therapy for SLE required long-term plaquenil
and prednisone. In September 1997 the patient was
admitted with progressive exertional dyspnoea, cardiac
decompensation, and a blowing systolic murmur at the
apex radiating to the left axilla. Transthoracic (TTE)
and transesophageal echocardiography (TEE) revealed
severe MR with thickened mitral valve leaflets and a
small vegetation on the posterior mitral valve leaflet.
Repeated blood cultures were negative and there was no
other evidence of infective endocarditis. The patient was
recompensated with diuretics and discharged. Echocar-
diographic follow-up over the following months revealed
a rapid increase in left ventricular diameters and normal
left ventricular (LV) function. Results of cardiac catheri-
zation are shown in Table 1. The patient underwent
mitral valve repair in March 1998. Intraoperative inspec-
tion showed slightly thickened, but otherwise surpris-
ingly normal leaflets. A small perforation was found in
the P2 section of the posterior leaflet. Preoperatively a
small vegetation was found near this location. Although
rare and more often seen in infectious endocarditis, leaf-
let perforation in LS endocarditis has been reported
before [16]. This patient’s history did not reveal any
documented thromboembolic events. A quadrangular
resection of the P2 section of the posterior mitral valve
leaflet was performed, followed by implantation of a 32
mm Carpentier-Edwards Classic annuloplasty ring.
Microscopic examination of the excised mitral valve seg-
ment revealed myxoid degeneration and no evident
signs of inflammation. Although evidence of LS
Figure 1 Verrucous vegetations seen in Libman-Sacks endocarditis of the mitral valve. The sterile fibrofibrinous vegetations seen in LS
endocarditis of the mitral valve may vary in size and typically have a wart-like morphology. They can be found near the edge of the leaflets
along the line of closure; both on the atrial and ventricular sides of the leaflets. They can even be found on the chordae and the endocardium.
In this case several microthrombi are present on the free edge of the leaflet and on the chordae. Reproduced with permission from
Dr. S. Gonzalez. Copyright 2009, department of Pathology, Pontifical Catholic University of Chile, Santiago, Chile.
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diagnosis was made based on the clinical features,
laboratory findings, and echocardiographic appearance.
The patient’s recovery from surgery was uneventful, and
he was discharged on the seventh postoperative day.
Echocardiographic follow-up revealed stable slight MR
from April 1998 through January 2009. When last seen
in March 2009, the patient was doing well, except for a
mild degree of dyspnoea.
Patient 2
A 56-year-old Caucasian man presented at our institu-
tion with severe SLE that had been diagnosed originally
in July 2003. Manifestations of his disease included
arthritis, pericarditis, and pleuritis without any evidence
of skin, cerebral or renal involvement. Laboratory find-
ings are shown in Table 1. His therapy for SLE required
long-term prednisone, plaquenil and azathioprine. On
routine examination in 2006 the patient appeared to
have a blowing systolic murmur at the apex radiating to
the left axilla. Transthoracic echocardiography (TTE)
revealed mitral valve thickening with focal vegetations
and severe MR. Repeated blood cultures were negative
and there was no other evidence of infectious endocar-
ditis. Results of cardiac catheterization are shown in
Table 1. The patient underwent mitral valve replace-
ment with a 31 mm St. Jude mechanical prosthesis in
October 2007. The excised mitral valve was thickened
and fibrotic with focal vegetations. Microscopic patholo-
gic examination of the excised mitral valve revealed
fibrosis, neovascularization, and vegetations with fibrin-
platelet thrombi and evident inflammatory cell infiltra-
tion (Fig 2A,B). LS endocarditis of the mitral valve was
confirmed. The patient’s recovery from surgery was
uneventful, and he was discharged on the seventh post-
operative day. Echocardiographic follow-up revealed no
M R .W h e nl a s ts e e ni nA p r i l2 0 0 9 ,t h ep a t i e n tw a s
doing well.
Table 1 Preoperative baseline characteristics of four patients with MR caused by LS endocarditis
Patient 1 2 3 4
Gender Male Male Female Female
Age (years) 49 56 28 22
SLE/APS SLE SLE APS APS
Years of SLE/APS 1.5 4 1 0.5
Steroids yes yes no no
Valve Lesion MR MR MR MR
NYHA class IV I III I
Echocardiography
-MR grade 4+ 4+ 4+ 2+
-LV function normal normal normal normal
Cardiac Catheterization
-Coronary artery disease no no no NA
-PAP (mmHg) (N: 15-30/3-12 mmHg) 34/6 41/18 32/21 NA
-PCWP (mmHg) (N: 1-10 mmHg) 10 18 21 NA
-LVEDP (mmHg) (N: 3-12 mmHg) 10 18 19 NA
-Cardiac Output (L/min/m
2) (N: 2.6-4.2 L/min/m
2) 2.74 3.20 4.30 NA
Laboratory tests
-Repeated blood cultures neg neg neg neg
-CRP (mg/l) (N: 0-5 mg/l) 38 60 3 34
-White blood cell count (×10
9/l) (N: 4.0-10.0 × 10
9/l) 4.6 3.8 6.8 8.9
-Thrombocyte count (×10
9/l) (N: 150-300 × 10
9/l) 258 249 105 114
-Lupus anticoagulant (N: neg) NA NA pos pos
-Anti-cardiolipin Ab (IgG) (U/ml) (N: <10 U/ml) <10 25 >100 53
-Anti-cardiolipin Ab (IgM) (U/ml) (N: <10 U/ml) <10 <10 <10 <10
-Complement C3 (g/l) (N: 0.90-1.80 g/l) 0.39 0.77 1.19 1.57
-Complement C4 (g/l) (N: 0.10-0.40 g/l) 0.13 0.19 0.31 0.39
-Anti-Nuclear Antibody (ANA) titer (N: <20) 320 >640 40 40
-Anti-ds-DNA Ab (Farr-assay) (U/ml) (N: <10 U/ml) 11 154 <3 5
-Extractable Nuclear Antigens (ENA) (N: neg) NA neg neg neg
Ab, antibodies; APS, anti-phospholipid syndrome; CRP, C-reactive protein; ds-DNA, double stranded DNA; LS, Libman-Sacks; LV(EDP), left ventricular (end-diastolic
pressure); MR, mitral regurgitation; N, normal values; NA, not available; NYHA, New-York heart association; PAP, pulmonary artery pressure; PCPW, pulmonary
capillary wedge pressure; SLE, systemic lupus erythematosus
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Page 3 of 13Figure 2 Microscopic histopathological examination of excised mitral valve tissue in patient 2 (A,B), 3 (C,D), and 4 (E,F).
(A) Photomicrograph of patient 2. Haematoxylin and Eosin (HE) stain of the atrial surface of the excised mitral valve anterior leaflet. Orginal
magnification × 25. (B) Magnified section of A. Original magnification × 400. Fibrinoid changes and neovascularization at the base of the
vegetation. The vegetation consists of fibrin-platelet thrombi and shows signs of acute and chronic inflammation with neutrophil and
mononuclear cell infiltration. (C) Photomicrograph of patient 3. HE stain of the atrial surface of the excised mitral valve posterior leaflet. Orginal
magnification × 50. (D) Magnified section of C. Original magnification × 400. Fibrinoid and hyaline changes at the base of the vegetation. The
vegetation itself shows signs of fibroblastic organization of fibrin-platelet thrombus and an inflammatory infiltrate with neutrophils. (E)
Photomicrograph of patient 4. HE stain of the atrial surface of the excised mitral valve posterior leaflet. Orginal magnification × 50. (F) Magnified
section of E. Original magnification × 200. Fibrinoid and myxoid degenerative changes at the base of the vegetation. The vegetation shows
signs of organization of fibrin-platelet thrombus without an evident inflammatory reaction. Sporadically, several neutrophils and mononuclear
cells can be found in this section. Black transparant rectangles outline magnified sections shown in the right-hand column. V: vegetation.
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A 28-year-old Caucasian woman was referred to our
institution in October 2006 with arthralgias and inter-
mittent haemoptysis. She had a missed abortion earlier
that year, when she was nine weeks pregnant. Labora-
tory findings are shown in Table 1. The patient was
diagnosed with primary APS. In November 2006 she
presented with exertional dyspnoea and a blowing systo-
lic murmur at the apex radiating to the left axilla.
Transthoracic echocardiography (TTE) revealed mitral
valve leaflet thickening with small vegetations on the
edges of both leaflets (Fig 3A,B) and severe MR with
backflow into the pulmonary veins (Fig 3C). Repeated
blood cultures were negative and there was no other
evidence of infectious endocarditis. Results of cardiac
catheterization are shown in Table 1. The patient under-
went mitral valve replacement in October 2007. Intrao-
perative inspection revealed thickened and fibrotic
mitral valve leaflets with focal vegetations (Fig 3D,E).
Therefore, mitral valve repair was not considered possi-
ble and the mitral valve was replaced with a 31 mm St.
Jude mechanical prosthesis. Microscopic pathologic
examination of the excised mitral valve revealed myxoid
and hyaline degeneration, fibrosis, and vegetations with
fibrin-platelet thrombi and evident inflammatory cell
infiltration (Fig 2C,D). LS endocarditis of the mitral
valve was confirmed. The patient’s recovery from sur-
gery was uneventful, and she was discharged on the
seventh postoperative day. Echocardiographic follow-up
revealed no MR. When last seen in June 2009, the
patient was doing well.
Patient 4
A 22-year-old Hispanic woman with a history of
hypothyreoidism was referred to our institution in
October 2007 after a transient ischemic attack of the
Figure 3 Two-dimensional TTE examination and intra-operative inspection of the mitral valve in patient 3. (A) Parasternal long-axis view,
systolic. (B) Apical four-chamber view, systolic. Morphologic examination of the mitral valve leaflets in both views revealed several structural
abnormalities, such as leaflet thickening and vegetations on the edges of both leaflets. (C) Severe MR as determined by jet area (13.4 mm
2)
divided by left atrial area (25.9 mm
2) (= 52%) and the vena contracta width (= 6 mm, not shown). (D) Superior view of the excised posterior
mitral valve leaflet (as seen from the left atrium). (E) Frontal view of the excised posterior mitral valve leaflet. Both views show marked
thickening and calcification of the posterior mitral valve leaflet and several thrombotic vegetations on the edge of the leaflet. Ao: aorta, LA: left
atrium, LV: left ventricle, MR: mitral regurgitation and V: vegetations.
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Page 5 of 13right cerebral hemisphere with temporary left hemiple-
gia. Routine trans-thoracic echocardiography revealed a
tumor with a diameter of approximately 1 cm on the
atrial side of the posterior mitral valve leaflet (Fig 4A,
B) as the source of this thrombo-embolic event. In
addition, a normal LV function and moderate (grade 2+)
MR was found (Fig 4C). Repeated blood cultures were
negative and there was no other evidence of infectious
endocarditis. Based on her history and the echocardio-
graphic appearance of the tumor the initial working
diagnosis was papillary fibroelastoma. Laboratory find-
ings are shown in Table 1. The patient was diagnosed
with primary APS. Subsequently, LS endocarditis of
the mitral valve was considered as an alternative diag-
nosis. To prevent future thrombo-embolic events the
patient was accepted for mitral valve surgery. Cardiac
catherization was not performed. The patient under-
went mitral valve repair in March 2008. Intraoperative
inspection showed a large verrucous tumor on the
atrial side of the P2 section of the posterior mitral
valve leaflet (Fig 4D). A quadrangular resection of the
P2 section of the posterior mitral valve leaflet was per-
formed (Fig 4E), followed by implantation of a 28 mm
Cosgrove-Edwards annuloplasty ring. Microscopic
examination of the excised mitral valve segment
revealed myxoid degeneration and large vegetations
with fibrin-platelet thrombi, but without an evident
inflammatory infiltrate (Fig 2E,F). The initial working
diagnosis of papillary fibroelastoma could not be con-
firmed on microscopic examination. A definite diagno-
sis of LS endocarditis was made. The patient’s recovery
from surgery was uneventful, and she was discharged
on the seventh postoperative day. Echocardiographic
follow-up after 1.5 years revealed no recurrence of
MR. When last seen in September 2009, the patient
was doing well.
Figure 4 Two-dimensional TTE examination and intra-operative inspection of the mitral valve in patient 4. Morphologic examination of
the mitral valve in both views revealed a 0.8 × 1.0 cm tumor on the posterior mitral valve leaflet; (A) Parasternal long-axis view, mid-diastolic;
(B) Apical four-chamber view, end-diastolic. (C) Mild-to-moderate MR as determined with colour-Doppler TTE; apical four-chamber view, systolic.
(D) Intra-operative inspection of the mitral valve (transseptal approach): a verrucous thrombotic tumor was found on the P2 section of the
posterior mitral valve leaflet. (E) The verrucous thrombotic tumor was removed with a quadrangular resection of P2. Ao: aorta, LA: left atrium,
LV: left ventricle, MR: mitral regurgitation and T: tumor.
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We systematically reviewed the literature on mitral valve
surgery for (isolated) MR caused by (SLE and/or APS
related) LS endocarditis (Table 2). We performed sepa-
rate Medline (PubMed), EMBASE, and Cochrane data-
base queries with the following text and keywords:
“libman-sacks endocarditis, mitral”, “antiphospholipid
syndrome, mitral”,a n d“non-bacterial thrombotic endo-
carditis, mitral”. All papers were considered irrespective
of their quality or the journal in which they were pub-
lished. We then used strict criteria. Titles and abstracts
were screened and relevant papers were selected. All
papers with a case report or a series of case reports on
mitral valve surgery for (isolated) MR caused by LS
endocarditis were included. Reports not written in Eng-
lish were excluded, as well as reports without a clear
description of MR etiology and/or mitral valve pathol-
ogy. In addition, cases of mitral valve surgery for mitral
stenosis (MS) (4 cases) or combined MR and MS (11
cases) caused by LS endocarditis were excluded.
Although these exclusions may be seen as a limitation,
we believe it is a particular strength of this study, since
it generated a “clean” cohort of patients that underwent
mitral valve surgery for (isolated) MR caused by Lib-
man-Sacks endocarditis.
Discussion
Nowadays LS endocarditis is seen as a cardiac manifes-
tation of both SLE and APS [2-5]. LS endocarditis is
usually typically mild and asymptomatic, but can lead to
serious complications, such as superimposed bacterial
endocarditis, thromboembolic events, and valvular
regurgitation and/or stenosis requiring surgery. The
mitral valve is most commonly affected [8,10]. The pre-
sence of APLs in patients with SLE is related to a higher
prevalence of valvular abnormalities [5,15], which sug-
gests a possible role for APLs in the pathogenesis.
Pathogenesis
At this point the exact pathogenesis of LS endocarditis is
still unclear. The initial insult to the valve, which causes
endothelial damage and elicits the pathogenetic sequence
of events, has not yet been identified. However, LS endo-
carditis has been assumed to involve the formation of
fibrin-platelet thrombi on the altered valve, the organiza-
tion of which leads to valve fibrosis, edema, diffuse thick-
ening, mild inflammatory changes, valve distortion,
scarring, and subsequent valvular dysfunction [5,7,17-19].
Both valve thickening and formation of vegetations repre-
sent different stages of the same pathological proces [5].
Immunologic injury has been postulated as a possible initi-
ating insult, since immunofluorescent microscopy revealed
deposition of immunoglobulins and complement on
affected valves [5,19]. Rather than playing a more direct
pathogenetic role, aPLs are thought to promote thrombus
formation on the endothelium of valves already compro-
mised by immune complex deposition, leading to further
valvular damage and inflammation [5,8,15,17,18,20,21].
Microscopy
Valvular LS lesions are microscopically characterized by
fibrin deposits at various stages of fibroblastic organiza-
tion, neovascularization, occasional haematoxylin bodies,
and by a variable extent of inflammation with mononuc-
lear cell infiltration [6,7]. Valvular lesions change over
time [10] and the end-stage or healed form of LS verru-
cous endocarditis is a fibrous plaque, sometimes with
focal calcification [5]. If the lesions are extensive
enough, their healing may be accompanied by marked
scarring, thickening, and deformity of the valve [5].
LS Endocarditis versus Non-Bacterial Thrombotic
Endocarditis (NBTE)
Microscopically, the mitral valve vegetations seen in SLE
are distinct from those seen in (primary) APS. A rather
remarkable difference is the absence (or minimal extent)
of inflammatory cell infiltration in (primary) APS [5,22].
To emphasize this difference some authors prefer to use
the term NBTE for the valve lesions seen in primary
APS instead of the term LS endocarditis. However,
others (including the authors of this study) prefer to use
the term LS endocarditis, because the two underlying
diseases are both auto-immune phenomena, are often
interrelated (APS secondary to SLE), and probably share
a (partially) similar pathologic pathway in causing valve
lesions.
Differentiation from infective endocarditis and
intracardiac tumors
Due to its asymptomatic nature establishing a diagnosis
of LS endocarditis can be rather difficult. This is further
complicated by the fact that the condition can mimick
intracardiac tumors [23-25] and bacterial endocarditis
("pseudoinfective” endocarditis) [26] or may coexist with
(superimposed) bacterial endocarditis (also known as
“double-decker” endocarditis) [7,26,27].
The modified Duke criteria can be useful in helping
differentiate between true infective endocarditis and LS
endocarditis [28]. Helpful laboratory markers in distin-
guishing infective endocarditis from LS endocarditis are
the white blood cell count (elevated in infective endo-
carditis and often decreased in LS endocarditis), C-reac-
tive protein levels (elevated in infective endocarditis and
relatively low in LS endocarditis), aPL levels (normal in
infective endocarditis and moderate to high in LS endo-
carditis), and (repeated) blood cultures (positive in
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Page 7 of 13Table 2 Systematic review of the English literature on mitral valve surgery for (isolated) MR caused by Libman-Sacks
endocarditis
a
Reference Year
published
Gender/
Age
(years)
SLE
and/
or
APS
Years
of SLE
and/or
APS
Steroids MR
grade
b
MVR/
MVP
Surgical procedure Follow-up
Myerowitz et al [48] 1974 F/22 SLE 3 yes 4+ MVR Reis-Hancock porcine bioprosthesis alive 2 months
post-op
Murray et al [49] 1975 F/43 SLE 2 yes 4+ MVR Beall Surgitoul mechanical prosthesis alive 6 months
post-op
Paget et al [50] 1975 F/18 SLE 4 yes 4+ MVR Porcine xenograft (bioprosthesis) alive 4 months
post-op
Kinney et al [51] 1980 F/27 SLE 0.3 no 4+ MVR Hancock porcine bioprosthesis NR
Rawsthorne et al [52] 1981 M/51 SLE 21 no 4+ MVR
c Hancock porcine bioprosthesis NR
Brennan et al [53] 1983 F/20 SLE 2 yes 4+ MVR Björk-Shiley mechanical prosthesis CVA 17 months
post-op
Rozman et al [54] 1986 M/43 SLE 2 yes NR MVR Starr-Edwards mechanical prosthesis alive 4 years
post-op
Moynihan et al [55] 1988 F/54 SLE 2 yes 4+ MVR
c Carpentier-Edwards porcine bioprosthesis alive 26
months post-
op
Straaton et al [56] 1988 F/22 SLE <1 no 4+ MVR
d Carpentier-Edwards heterograft
(bioprosthesis)
NR
F/67 SLE 10 yes 2+/3+ MVR
c St. Jude mechanical prosthesis died
intraoperatively
Ferraris et al [57] 1990 M/34 SLE 9 yes 4+ MVR Carpentier-Edwards bioprosthesis alive 2.5 years
post-op
Alvarez et al [58] 1994 F/42 APS 1 no 2+/3+ MVR Medtronic Hall mechanical prosthesis NR
Kalangos et al [40] 1995 F/28 SLE 0.5 yes 4+ MVP Resection of the prolapsed posterior
commissure and restoration with an
autologous pericardial patch; sliding
plasty of the anterior leaflet; transposition
of secondary chordae to the commisure;
Carpentier- Edwards annuloplasty ring
no MR
recurrence 1
year post-op
Chauvaud et al [41] 1995 F/17 SLE 5 yes 4+ MVP Posterior leaflet enlargement with
pericardial
patch and Carpentier-Edwards
annuloplasty ring
MS 6 months
post-op
due to
calcification
redo
MVR
Cryopreserved homograft alive 1 year
post-op
Shahian et al [59] 1995 F/29 APS 0 yes 4+ MVR St. Jude mechanical prosthesis alive 2 years
post-op
Gordon et al [46] 1996 M/37 SLE,
APS
>2 yes 1+/2+ MVR
c Carpentier-Edwards porcine bioprosthesis recurrent A-V
fistula
redo
MVR
Carpentier-Edwards porcine bioprosthesis died 1 month
post-op
Morin et al [33] 1996 F/40 SLE 12 yes 4+ MVR St. Jude mechanical prosthesis alive 2 weeks
post-op
East et al [60] 2000 F/51 SLE,
APS
NR no 4+ MVR
e not further specified NR
F/49 SLE,
APS
7 yes 4+ MVR not further specified NR
Hakim et al [42] 2001 F/23 SLE 8 yes 4+ MVR St. Jude mechanical prosthesis alive >1 year
post-op
F/54 SLE 7 yes 4+ MVP
f not further specified MR 29 months
post-op
redo
MVR
St. Jude mechanical prosthesis alive >5 years
post-op
F/64 SLE 2 yes 4+ MVP
e Quadrangular resection of the posterior
leaflet and Duran annuloplasty ring
alive >3 years
post-op
Kato et al [43] 2001 F/52 APS NR no 4+ MVP Kay’s annuloplasty and Cosgrove
annuloplasty ring
alive 3 months
post-op
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endocarditis
a (Continued)
Mottram et al [23] 2002 M/50 APS 0 no 0/1+ MVP Removal of two mitral valve masses alive 9 weeks
post-op
da Silva et al [47] 2003 F/54 SLE,
APS
13 yes 4+ MVR Bioprosthesis (not further specified) bioprosth.
thrombosis and
death 9
months post-
op
Schneider et al [44] 2003 M/23 SLE NR NR 4+ MVP not further specified NR
Georghiou et al [61] 2003 F/44 SLE 1 yes 3+ MVR
c,d St. Jude mechanical prosthesis alive 6 months
post-op
Bordin et al [62] 2003 F/57 SLE,
APS
3 NR 4+ MVR Mechanical prosthesis (not further
specified)
MI 2 days post-
op
Berkun et al [63] 2004 F/48 APS NR yes 3+/4+ MVR Carbomedics mechanical prosthesis MR 90 months
post-op
redo
MVR
not further specified died 6 months
post-op
F/73 APS NR yes 3+/4+ MVR Hancock porcine bioprosthesis died 13
months post-
op
F/47 APS NR yes 3+/4+ MVR
c Carbomedics mechanical prosthesis splenic
embolus 3 and
CVA 10 months
post-op
alive 42
months post-
op
F/38 SLE,
APS
NR yes 3+/4+ MVR Carbomedics mechanical prosthesis alive 32
months post-
op
F/51 SLE,
APS
NR yes 3+/4+ MVR Carbomedics mechanical prosthesis alive 33
months post-
op
Fernández et al [45] 2005 F/36 SLE 8 NR 4+ MVP not further specified mild MR 1 year
post-op
Taguchi et al [24] 2006 F/34 SLE 9 yes 0/1+ MVP Resection of A3 and attached chordae
(en-bloc);
restoration of the anterior leaflet; 4 PTFE
neochordae
no MR
recurrence 6
months post-
op
Einav et al [64] 2007 F/28 SLE,
APS
4.5 yes 4+ MVR
c,d Mechanical prosthesis (not further
specified)
NR
Takayama et al [16] 2008 M/58 SLE,
APS
0 no 3+/4+ MVP Valvuloplasty and annuloplasty (not
further specified)
NR
Bouma et al 2010 M/49 SLE 1.5 yes 4+ MVP Quadrangular resection of the posterior
stable trace MR leaflet (P2) and
Carpentier-Edwards annuloplasty ring
stable trace MR
11 years post-
op
M/56 SLE 4 yes 4+ MVR St. Jude mechanical prosthesis alive >1.5 years
post-op
F/28 APS 1 no 4+ MVR St. Jude mechanical prosthesis alive >1.5 years
post-op
F/22 APS 0.5 no 2+ MVP Quadrangular resection of the posterior
leaflet (P2) and Cosgrove-Edwards
annuloplasty ring
no MR
recurrence 1.5
years post-op
A-V, atrioventricular; APS, antiphospholipid syndrome; CVA, cerebrovascular accident; F, female; M, male; MI, myocardial infarction; MR, mitral regurgitation; MS,
mitral stenosis;MVP, mitral valve plasty; MVR, mitral valve repair; NR, not reported; PTFE, polytetrafluorethylene; SLE, systemic lupus erythematosus
areports not written in English or reports of mitral valve surgery in patients with SLE and/or APS without a description of MR etiology and mitral valve pathology
were excluded; cases of MS (n = 4) or combined MR/MS (n = 11) caused by Libman-Sacks endocarditis were also excluded
bMR severity grading: 0, no or trace MR; 1+, mild MR; 2+, moderate MR; 3+, moderate-to-severe MR; 4+, severe MR
cincluding aortic valve replacement (AVR)
dincluding tricuspid valve plasty (TVP)
eincluding CABG
fincluding aortic valve plasty (AVP)
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[21,29]. Echocardiographically, LS vegetations appear as
valve masses of varying size and shape with irregular
borders and echodensity, they are firmly attached to the
valve surface and exhibit no independent motion [8].
Contrary to the vegetations of infective endocarditis,
which typically exhibit independent motion [30].
As previously demonstrated [23-25] and as we showed
in patient 4, differentiation from intracardiac tumors
can also be difficult. Although LS vegetations are usually
typically sessile, wartlike, and small, varying from pin-
head size to 3-4 mm [5], they can become rather large
making them difficult to distinguish (echocardiographi-
cally) from a typical mitral valve tumor such as papillary
fibroelastoma. On echocardiography papillary fibroelas-
t o m au s u a l l ya r i s ev i aap e d i c l ef r o mm i t r a lv a l v et i s s u e
or adjacent endocardium, and have a characteristic
frond-like appearance [31]. A remarkable feature that LS
vegetations do not posses.
Recently, a prospective randomized controlled study
showed that TEE was superior to TTE in diagnosing LS
endocarditis [32]. Nevertheless, establishing the diagno-
sis remains challenging.
Treatment with corticosteroids and anticoagulation
Corticosteroids do not prevent LS endocarditis, but they
facilitate healing of LS lesions over time by decreasing
the amount of inflammation [5,33-35]. However, they
can increase fibrosis and scarring, ultimately worsening
valvular damage and dysfunction [5,33-35]. Nonetheless,
appropriate steroid therapy to control SLE disease activ-
ity is important.
The risk of thrombo-embolic events (mainly stroke
and transient ischaemic attacks) is increased in LS endo-
carditis [8]. Current therapeutic guidelines for APS
include thrombo-embolic prevention with long-term
anticoagulation [5]. In addition, patients with LS endo-
carditis who have suffered a thrombo-embolic event are
recommended to be on lifelong anticoagulation for pre-
vention of future thrombo-embolic events [5]. Moreover,
implantation of a mechanical valve requires anticoagula-
tion and atrial fibrillation is frequently a concomitant
condition necessitating anticoagulation in patients with
severe MR. In other words, lifelong anticoagulation can
often not be avoided in these patients.
Mitral valve surgery
In most patients hemodynamically important valvular
dysfunction can be controlled with conservative treat-
ment (i.e immunosuppression, anticoagulation, endocar-
ditis profylaxis, and specific heart failure treatment
including ACE-inhibitors, beta-blockers, diuretics)
[5,36,37]. However, if severe symptomatic valvular dys-
function persists mitral valve surgery may be required.
Valve repair versus replacement and valve selection
In contemporary cardiac surgery mitral valve repair has
become the mainstay of surgical treatment for most
causes of MR. Particularly, in the last two decades there
has been a gradual shift from mitral valve replacement
to mitral valve repair for MR caused by a broad range
of etiologies. Several general advantages of mitral valve
repair over replacement include a lower operative mor-
tality rate, higher survival rates, better maintainance of
left ventricular function, a lower risk of endocarditis, a
lower risk of thrombo-embolic complications, less use of
lifelong anticoagulation, and lower costs [38,39].
In recent years mitral valve repair for significant MR
due to LS endocarditis has been described in 10 patients
(Table 2) [16,23,24,40-45]. Unfortunately the exact sur-
gical repair techniques were not described in 4 of these
patients [16,42,44,45]. In this report we added two
mitral valve repair cases to the literature with a precise
description of mitral valve pathology and mitral valve
repair techniques. In both patients (one with SLE and
one with primary APS) intraoperative macroscopic
examination revealed only localized abnormalities with
otherwise relatively normal leaflets. Therefore mitral
valve repair was considered a good surgical option in
these two patients. Echocardiographic and clinical fol-
low-up of both patients after 11 and 1.5 years, respec-
tively, showed excellent results and no recurrence of
MR. To our knowledge, this is the longest follow-up
ever described after mitral valve repair for MR caused
by LS endocarditis.
Some studies suggest that results of mitral valve repla-
cement (MVR) are usually superior to repair for LS
endocarditis [41,42]. According to these studies, severe
(ongoing) calcification and fibrosis lead to rapid recur-
rence of MR after repair with a subsequent reoperation
and MVR [41,42]. In our systematic review we found
two cases of MVR after initial repair for MR due to LS
endocarditis [41,42]. In the first case severe mitral ste-
nosis developed 6 months after mitral valve repair due
to ongoing calcification [41] and in the second case
severe MR recurred 29 months after repair [42].
Taken together, we believe mitral valve repair for LS
endocarditis of the mitral valve can be justified in speci-
fic patients. If SLE and/or APS has been relatively stable
(with immunosuppresive therapy) in a young patient, if
intraoperative macroscopic examination reveals rela-
tively normal leaflets with only localized abnormalities,
and if repair seems feasible, then mitral valve repair is
in our opinion certainly justified and probably the pre-
ferred surgical option. Especially in young females, who
are likely to become pregnant in the near future, long-
term anticoagulation is preferably avoided by mitral
valve repair. However, as previously mentioned, anticoa-
gulation is often still necessary in LS endocarditis and
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case mitral valve replacement with preservation of the
subvalvular apparatus may be a good surgical alternative.
In case of mitral valve replacement, prosthetic valve
selection is highly individualized based on age and other
factors. In patients with bleeding abnormalities the
superiority of bioprosthetic valves over mechanical
valves is clear. However, mechanical valve replacement
is recommended in patients at low risk with anticoagu-
lation and at high risk for bioprosthetic valve calcifica-
tion. Although succesful placement of porcine
bioprostheses in patients with LS endocarditis has been
reported (Table 2), complications can arise. In our sys-
tematic review we found one case in which a biopros-
thetic porcine valve had to be replaced, because it was
affected by (rapid) calcification and valvulitis and subse-
quent perforation [46] and another case in which mas-
sive bioprosthetic thrombosis occurred [47]. Again
stressing the importance of anticoagulation in this dis-
ease. In addition, (SLE associated) renal failure can
accelerate bioprosthetic degeneration as a consequence
of abnormal calcium and phosphate metabolism [40].
Therefore, a mechanical prosthesis may provide better
results than a bioprosthesis for MR caused by LS endo-
carditis, even though mechanical prostheses carry a
higher risk of thrombo-embolic complications.
Evidently, no definite consensus has been reached at
this point as to whether or not these valves should be
replaced or repaired and whether a mechanical prosthe-
sis is more advantageous than a bioprosthesis.
Conclusion
LS endocarditis should be strongly suspected when sig-
nificant valve dysfunction, such as MR, develops during
the course of SLE and/or APS. Differentiation from
infective endocarditis and intracardiac tumors can be
difficult, but is important and has different therapeutic
implications. After establishing the diagnosis, periodic
echocardiographic follow-up is recommended to detect
detoriation of valvular function. When severe sympto-
matic MR requires surgery, mitral valve repair should
always be considered. This report showed that mitral
valve repair is feasible and effective in young patients
with relatively stable SLE and/or APS and only localized
mitral valve abnormalities caused by LS endocarditis.
Both clinical and echocardiographic follow-up showed
excellent mid- and long-term results.
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